, 15 tweets, 5 min read Read on Twitter
My only #ASCO19 Tweets will be in this thread. I will post a few abstracts of negative trials with and without positive spin. Things not to do as of June 2019.
This is somewhat obvious, but in case you didn't know, do not give rituximab maintenance for DLBCL. meetinglibrary.asco.org/record/174772/…
Despite these deceptive conclusions, do not use pembrolizumab in
HCC in the second-line setting. meetinglibrary.asco.org/record/173190/…
Do not get overly excited about a PFS endpoint in a lethal disease like pancreatic cancer meetinglibrary.asco.org/record/174488/…
When you have a patient with advanced soft tissue sarcoma, do not give them olaratumab. meetinglibrary.asco.org/record/174690/…
Don't blast patients with metastatic colorectal cancer with FOLFOXIRI + bev because of a 3 month median PFS difference, and no OS difference. meetinglibrary.asco.org/record/171164/…
Don't add abiraterone to enzalutamide in metastatic CRPC. More is not better in this case. meetinglibrary.asco.org/record/172903/…
There is no need to give patients with metastatic CRPC diarrhea by giving them 2 grams of metformin when they will be getting docetaxel for their cancer. meetinglibrary.asco.org/record/172957/…
Again, despite deceptive conclusions, pembrolizumab +chemo is not superior to EXTREME regimen in overall population of metastatic head and neck cancer, specifically in CPS 0%. meetinglibrary.asco.org/record/171051/…
More regimens trying to beat EXTREME but failing. Docetaxel, cisplatin, cetuximab + maintenance cetuximab is not superior to EXTREME. Do not conclude equivalence in a superiority trial. meetinglibrary.asco.org/record/171046/…
If you come across some more informative negative trials please reply to this thread..
Can we call this a negative trial? Or maybe a positive trial that is not so positive for patients.
Let me add a few more.

Durvalumab +/- tremelimumab in second-line metastatic head and neck cancer not better than SOC chemo (including methotrexate!). Do not use durvalumab. meetinglibrary.asco.org/record/175441/…
Interesting study in adjuvant non-squamous NSCLC where pemetrexed/cisplatin not proven to be superior to vinorelbine/cisplatin. meetinglibrary.asco.org/record/173488/…
Pazopanib/gemcitabine in second-line metastatic STS not superior to SOC gemcitabine/docetaxel. meetinglibrary.asco.org/record/175014/…
Missing some Tweet in this thread?
You can try to force a refresh.

Like this thread? Get email updates or save it to PDF!

Subscribe to Talal Hilal
Profile picture

Get real-time email alerts when new unrolls are available from this author!

This content may be removed anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!